SCHEMBL833335

SCHEMBL833335

C=COc1ccc(Br)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.42
MAPT P10636 2/20 0.41
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
LDHA P00338 1/20 0.35
TGM2 P21980 3/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
F13A1 P00488 1/20 0.34
TGM1 P22735 1/20 0.34
TGM3 Q08188 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 2/20 0.33
APP P05067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vinyl Ether SCHEMBL1412752 0.93 MAPT (0.37) CYP2A6MAPTCA1CA2CA9
SCHEMBL473606 0.86 CHRNB2 (0.34) MAPTCA1CA2CA9LMNA
SCHEMBL14289128 0.78 ALDH1A1 (0.44) MAPTTGM2LMNAMAPK1MEN1
SCHEMBL11965976 0.78 ESR2 (0.33) MAPTLMNAMAPK1RAB9AALDH1A1
SCHEMBL1412755 0.77 MAPT (0.32) CYP2A6MAPTCA1CA2CA9
SCHEMBL3791265 0.75 CYP2A6 (0.38) CYP2A6MAPTCA1CA2CA9
SCHEMBL3791263 0.75 CYP2A6 (0.38) CYP2A6MAPTCA1CA2CA9
SCHEMBL24636596 0.74 CHRNB2 (0.30)
SCHEMBL126186 0.74 ALDH1A1 (0.58) CYP2A6LMNAALDH1A1
SCHEMBL17186614 0.74 NPC1 (0.32) MAPTLMNAMAPK1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof KAUNAS UNIVERSITY OF TECHNOLOGY (LT) 2024-10-17 US disclosed
EP-4447643-A1 IN-SITU CROSSLINKING OF 9,9`-SPIROBIFLUORENE-BASED COMPOUNDS FOR USE IN OPTOELECTRONIC AND/OR PHOTOELECTROCHEMICAL DEVICES AND MANUFACTURE THEREOF Kaunas University of Technology (LT) 2024-10-16 EP disclosed
CN-113666883-B Method for synthesizing 4-vinyl isoxazole derivative 华南理工大学 2023-06-16 CN disclosed
EP-3555055-B1 HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME LLC (US) 2022-08-03 EP disclosed
CN-113666883-A Method for synthesizing 4-vinyl isoxazole derivative 华南理工大学 2021-11-19 CN disclosed
US-10864211-B2 Hydroxy isoxazole compounds useful as GPR120 agonists MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
EP-3555055-A1 HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS Merck Sharp & Dohme Corp. (US) 2019-10-23 EP disclosed
US-20190269679-A1 HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2019-09-05 US disclosed
WO-2018111734-A1 HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2018-06-21 WO disclosed
US-9617256-B2 Antibacterial agents ACHAOGEN, INC. (US) 2017-04-11 US disclosed
US-20020197551-A1 Toner, and process for producing toner TAZAWA YAYOI (JP) 2002-12-26 US disclosed
CN-1384401-A Compensating developer and developing method CANON KK (JP) 2002-12-11 CN disclosed
EP-1237051-A2 Replenishing developer and developing method CANON KABUSHIKI KAISHA (JP) 2002-09-04 EP disclosed
US-6372400-B1 FOR DEVELOPING AN ELECTROSTATIC LATENT IMAGE BY ELECTROPHOTOGRAPHY CANON KABUSHIKI KAISHA (JP) 2002-04-16 US disclosed
US-6358658-B1 COLOR TONERS AND BINDERS CANON KABUSHIKI KAISHA (JP) 2002-03-19 US disclosed
EP-0801335-B1 Magnetic coated carrier, two-component type developer and developing method CANON KK (JP) 2001-08-29 EP disclosed
EP-1065571-A2 Carrier for use in electrophotography, two-component type developer and image forming method CANON KABUSHIKI KAISHA (JP) 2001-01-03 EP disclosed
US-6165663-A Magnetic coated carrier two-component type developer and developing method CANON KABUSHIKI KAISHA (JP) 2000-12-26 US disclosed
EP-1003080-A1 Toner, and process for producing toner CANON KABUSHIKI KAISHA (JP) 2000-05-24 EP disclosed
EP-0801335-A1 Magnetic coated carrier, two-component type developer and developing method CANON KABUSHIKI KAISHA (JP) 1997-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof INTS9, SLC6A9, SLC19A1 CYP2A6 1243/4885MAPT 473/4885CA1 4264/4885
US-10864211-B2 Hydroxy isoxazole compounds useful as GPR120 agonists GPR119, GPR88, GPR180 CYP2A6 1558/4885MAPT 4490/4885CA1 4632/4885
US-20190269679-A1 HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS GPR119, GPR88, GPR180 CYP2A6 1558/4885MAPT 4490/4885CA1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.